{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:06:42Z","timestamp":1763536002218,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12664-021-01227-y","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T13:02:53Z","timestamp":1661605373000},"page":"352-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Factors affecting prognosis in hepatocellular carcinoma patients post-transarterial chemoembolization"],"prefix":"10.1007","volume":"41","author":[{"given":"Tanaporn","family":"Prateepchaiboon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-2685","authenticated-orcid":false,"given":"Arunchai","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuttanit","family":"Pungpipattrakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerati","family":"Akarapatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attapon","family":"Rattanasupar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apiradee","family":"Songjamrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songklod","family":"Pakdeejit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"key":"1227_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450\u201362.","journal-title":"N Engl J Med"},{"key":"1227_CR2","doi-asserted-by":"publisher","first-page":"107327481772924","DOI":"10.1177\/1073274817729245","volume":"24","author":"NN Massarweh","year":"2017","unstructured":"Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245.","journal-title":"Cancer Control"},{"key":"1227_CR3","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1007\/s10620-013-2562-8","volume":"58","author":"YJ Jin","year":"2013","unstructured":"Jin YJ, Chung YH, Kim JA, et al. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. Dig Dis Sci. 2013;58:1758\u201365.","journal-title":"Dig Dis Sci"},{"key":"1227_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver (EASL)","year":"2018","unstructured":"European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"1227_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"1227_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jvir.2012.12.013","volume":"24","author":"R Golfieri","year":"2013","unstructured":"Golfieri R, Renzulli M, Mosconi C, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013;24:509\u201317.","journal-title":"J Vasc Interv Radiol"},{"key":"1227_CR7","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734\u20139.","journal-title":"Lancet"},{"key":"1227_CR8","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.11111","volume":"97","author":"OM Ebied","year":"2003","unstructured":"Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2003;97:1042\u201350.","journal-title":"Cancer"},{"key":"1227_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","volume":"131","author":"K Takayasu","year":"2006","unstructured":"Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461\u20139.","journal-title":"Gastroenterology"},{"key":"1227_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2036.2011.04694.x","volume":"34","author":"G Cabibbo","year":"2011","unstructured":"Cabibbo G, Genco C, Di Marco V, et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther. 2011;34:196\u2013204.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/hep.23725","volume":"52","author":"R Lencioni","year":"2010","unstructured":"Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762\u201373.","journal-title":"Hepatology"},{"key":"1227_CR12","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.31557\/APJCP.2018.19.12.3545","volume":"19","author":"K Bannangkoon","year":"2018","unstructured":"Bannangkoon K, Hongsakul K, Tubtawee T, McNeil E, Sriplung H, Chongsuvivatwong V. Rate and predictive factors for sustained complete response after selective transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Asian Pac J Cancer Prev. 2018;19:3545\u201350.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1227_CR13","doi-asserted-by":"crossref","unstructured":"Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 118:16\u221222","DOI":"10.3109\/03009734.2012.729104"},{"key":"1227_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-2008-1040525","volume":"8","author":"BF Grant","year":"1988","unstructured":"Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis. 1988;8:12\u201325.","journal-title":"Semin Liver Dis"},{"key":"1227_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"1227_CR16","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.jhep.2015.01.022","volume":"62","author":"BK Kim","year":"2015","unstructured":"Kim BK, Kim SU, Kim KA, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015;62:1304\u201310.","journal-title":"J Hepatol"},{"key":"1227_CR17","first-page":"294","volume":"47","author":"S Chonprasertsuk","year":"2017","unstructured":"Chonprasertsuk S, Vilaichone RK. Epidemiology and treatment of hepatocellular carcinoma in Thailand. Jpn J Clin Oncol. 2017;47:294\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"1227_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.5009\/gnl16001","volume":"11","author":"SO Jeong","year":"2017","unstructured":"Jeong SO, Kim EB, Jeong SW, et al. Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma. Gut Liver. 2017;11:409\u201316.","journal-title":"Gut Liver"},{"key":"1227_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","volume":"70","author":"N Ganne-Carri\u00e9","year":"2019","unstructured":"Ganne-Carri\u00e9 N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70:284\u201393.","journal-title":"J Hepatol"},{"key":"1227_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.cld.2012.08.011","volume":"16","author":"P Grewal","year":"2012","unstructured":"Grewal P, Viswanathen VA. Liver cancer and alcohol. Clin Liver Dis. 2012;16:839\u201350.","journal-title":"Clin Liver Dis"},{"key":"1227_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ypmed.2003.11.027","volume":"38","author":"G Corrao","year":"2004","unstructured":"Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med. 2004;38:613\u20139.","journal-title":"Prev Med"},{"key":"1227_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1188\/08.CJON.759-766","volume":"12","author":"VC Sun","year":"2008","unstructured":"Sun VC, Sarna L. Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs. 2008;12:759\u201366.","journal-title":"Clin J Oncol Nurs"},{"key":"1227_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1191\/0269216304pm851oa","volume":"18","author":"M-H Lin","year":"2004","unstructured":"Lin M-H, Wu P-Y, Tsai S-T, Lin C-L, Chen T-W, Hwang S-J. Hospice palliative care for patients with hepatocellular carcinoma in Taiwan. Palliat Med. 2004;18:93\u20139.","journal-title":"Palliat Med"},{"key":"1227_CR24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/jgh.12873","volume":"30","author":"K Qu","year":"2015","unstructured":"Qu K, Yan Z, Wu Y, et al. Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1\u03b1 dependent pathway in hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30:925\u201332.","journal-title":"J Gastroenterol Hepatol"},{"key":"1227_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1177\/2050640619840199","volume":"7","author":"B Scheiner","year":"2019","unstructured":"Scheiner B, Ulbrich G, Mandorfer M, et al. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterol J. 2019;7:850\u20138.","journal-title":"United European Gastroenterol J"},{"key":"1227_CR26","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00432-020-03331-6","volume":"146","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146:2439\u201346.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1227_CR27","first-page":"33","volume":"62","author":"A Abbasi","year":"2012","unstructured":"Abbasi A, Bhutto AR, Butt N, Munir SM. Corelation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma. J Pak Med Assoc. 2012;62:33\u20136.","journal-title":"J Pak Med Assoc"},{"key":"1227_CR28","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","volume":"146","author":"T Yau","year":"2014","unstructured":"Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146:1691-700.e3.","journal-title":"Gastroenterology"},{"key":"1227_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/hep.510280322","volume":"28","author":"The Cancer of the Liver Italian Program (CLIP) investigators","year":"1998","unstructured":"The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751\u20135.","journal-title":"Hepatology"},{"key":"1227_CR30","doi-asserted-by":"publisher","first-page":"e183213","DOI":"10.1001\/jamanetworkopen.2018.3213","volume":"1","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Zhang M, Chen M, et al. Association of sustained response duration with survival after conventional transarterial chemoembolization in patients with hepatocellular carcinoma. JAMA Netw Open. 2018;1:e183213.","journal-title":"JAMA Netw Open"},{"key":"1227_CR31","first-page":"1708","volume":"101","author":"A Chang","year":"2018","unstructured":"Chang A, Utarabhand R, Khaimook A, Songjamrat A, Pakdeejit S, Rattanasupa A. Adherence to AASLD recommendation guideline for treatment hepatocellular carcinoma: single center analysis of the regional hospital of Thailand. J Med Assoc Thai. 2018;101:1708\u201315.","journal-title":"J Med Assoc Thai"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-021-01227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-021-01227-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-021-01227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T01:12:52Z","timestamp":1664845972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-021-01227-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s12664-021-01227-y","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"type":"print","value":"0254-8860"},{"type":"electronic","value":"0975-0711"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"27 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TP, AC, NP, KA, AR, AS, SP, and TP declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the Institutional Review Board of Hatyai Hospital (number 53\/2564) and carried out according to the Declaration of Helsinki. The need for written informed consent was waived because of the retrospective nature of the study and the anonymization of patient information prior to analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors are solely responsible for the data and the content of the paper. In no way are the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology,\u00a0or the printer\/publishers responsible for the results\/findings and content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}